Alymsys (Bevacizumab)

Generic Name

Bevacizumab

Brand Names

Alymsys, Avzivi tnjn, Avastin, Jobevne, Zirabev, MVASI, Avzivi, Vegzelma

FDA approval date: February 26, 2004

Classification: Vascular Endothelial Growth Factor Inhibitor

Form: Injection

What is Alymsys (Bevacizumab)?

MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Homologous Recombinant Deficient (HRD +) Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug, Other

Study Phase: Phase 3

Summary: Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive sur...

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

View All Clinical Trials